Centro De Ingenieria Genetica Y Biotecnologia

Centro De Ingenieria Genetic Y Biotechnologia

Julio César Aguilar Rubido

Gerardo Enrique Guillén Nieto

Enrique Iglesias Perez

Eduardo Pentón Arias

Sonia Gonzalez Blanco

Yadira Lobaina Mato

Jorge Valdes Hernandez

Mariela Vazquez Castillo

Viviana Falcon Cama

Jorge Agustín Aguiar Santiago

Eduardo Penton Arias

Mariela Vazquez Catillo

Jorge Agustin Aguiar Santiago

Dagmara Pichardo Díaz

Verena L Muzio González

Daniel O Palenzuela Gardón

Dina Tleugulova

Minerva Sewer Mensies

Iloki Assanga Simon Bernard

Yanet Tambara Hernandez

Luis Javier Cruz Ricondo

Gerardo Enrique Guill Nenieto

This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.

Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus

The present invention is related to the branch of medicine, particularly to the new formulations of vaccine antigens. The technical objective pursued with the present invention is, precisely, the development of formulations that are able to enhance the immune response to mucosally administered antigens, minimising the number of compounds in the formulation and generating strong mucosal and systemic responses through a synergic interaction between the antigens in the formulation. These formulations enable: a) to broaden the spectrum of the anti-hepatitis B immune response, containing as main compounds HBsAg and HBcAg, b) to enhance the response against HBsAg with a viral nucleocapsid c) to generate combined vaccines through the mucosal route with HBsAg as a central antigen. Stabilizers and preservatives can be introduced. The formulations of this invention can be applied in the pharmaceutical industry as human or veterinary vaccine formulations.

Compositions containing virus-like particles as immunopotentiators administered through the mucosa

Growing community of inventors

La Habana, Cuba

Julio César Aguilar Rubido